Available Technologies

Find technologies available for licensing from UCLA.

No technologies match these criteria.
Schedule UC TechAlerts to receive an email when technologies are published that match this search. Click on the Save Search link above

New Molecular Tweezers Against Neurological Disorders And Viral Infections

UCLA researchers in the Department of Neurology with an international team of scientists have developed several new molecular tweezer derivatives with novel synthesis methods that significantly improved the therapeutic efficacy and pharmacokinetic characteristics of the drug candidates.

Sustained Intracellular RNA Delivery and Expression

UCLA researchers in the Department of Chemistry and Biochemistry have developed a novel method for high protein expression levels, in situ, involving RNA-based therapeutics.

Allosteric BACE Inhibitors For Treatment Of Alzheimer’s Disease

UCLA researchers from the Department of Neurology have discovered a new class of drug candidates for Alzheimer’s disease. These small molecule compounds can specifically inhibit target enzymes to prevent target protein cleavage through an allosteric mechanism, preventing off-target side effect.

Inhibitors Of The N-Terminal Domain Of The Androgen Receptor

UCLA researchers under the guidance of Drs. Matthew Rettig and Mike Jung have developed a novel family of therapeutics for use against castration resistant prostate cancer. These drugs have been shown to inhibit the androgen receptor and are unaffected by the most common drug-resistant mutations found in prostate cancer patients.

Second-Generation Estrogen Receptor Down-Regulators for Medical Therapy

UCLA researchers in the School of Medicine have developed a series of novel estrogen receptor antagonists for breast cancer therapy.

Small Molecules to Facilitate Therapeutic Exon Skipping

Investigators at UCLA have discovered a series of small molecules to facilitate therapeutic exon skipping. The use of these identified molecules may enhance the effectiveness of antisense oligonucleotide agents currently in clinical development.

Trehalose Hydrogels For Stabilization And Delivery Of Proteins

UCLA researchers in the Department of Chemistry and Biochemistry have developed a novel trehalose hydrogel to help stabilize proteins for drug delivery.

Novel Antiviral Compounds to Treat Enterovirus Infections

Researchers in UCLA Department of Molecular & Medical Pharmacology have used a rapid, live virus assay to develop potent enterovirus inhibitors.

Vectors for Antibody Expression

Brief description not available

Netrin-1 Compounds as Post-MI and Post-Angioplasty Therapeutics as well as for Treating Renal and CNS Reperfusion Injury

UCLA researchers have invented a method of decreasing myocardial injury and infarct size through the intravenous administration of the netrin-1 or netrin-1-derived peptides during a cardiac event. These agents have powerful cardioprotective effects and provide a novel and effective therapy for the treatment of myocardial infarction.

Antibody Therapy for Inhibiting Bladder Cancer and Prostate Cancer Metastasis

UCLA has a robust intellectual property position on antibody-based diagnostics and therapeutics against N-cadherin for the treatment and detection of prostate and bladder cancers. The research and development leading to this promising technology has been conducted by Dr. Robert Reiter, Professor of Urology and Director of UCLA’s Prostate Cancer Program.

Highly-Stablized Nanocapsules for siRNA Delivery

UCLA scientists have developed novel nanocapsules that facilitate efficient siRNA delivery into cells. The invention represents a significant advancement in realizing therapeutics based on targeted reduction of gene expression.  

Novel Non-Peptidomimetic Prenyltransferase Inhibitors

UCLA Researchers in the Department of Chemistry & Biochemistry and School of Medicine have synthesized a series of small molecule therapeutics against GGTase-I and GGTase-II, both of which are critical oncology drug targets.

Identification And Development Of Dual nSMase2-AChE Inhibitors For Neurodegenerative Disorders

UCLA researchers in the Department of Neurology, and the Department of Chemistry & Biochemistry have developed small molecule inhibitors of both the neutral sphingomyelinase 2 (nSMase2) and acetylcholinesterase (AChE) as novel therapeutics for neurodegenerative disorders caused by protein aggregation.

Exercise In A Pill: Compounds That Reproduce The Effects Of Exercise On Muscle Metabolism And Growth

UCLA researchers in the Department of Neurology have identified and synthesized small molecule analogs that activate skeletal muscle growth, mediated by calcium calmodulin kinase II signaling.

Inhibition Of Protein Tyrosine Phosphatase - Sigma For Hematopoietic Regeneration

UCLA Researchers have identified a novel pharmacological target for hematopoietic stem cell regeneration. They have developed small molecule inhibitors against the target and shown that the inhibitors cause rapid stem cell regeneration.

Peripherally-Acting Cannabinoid Receptor Agonists for Chronic Pain

Researchers from UCLA and RTI International have developed novel, small molecule agonists at cannabinoid type 1 and type 2 receptors (CB1R and CB2R) that have low blood-brain barrier (BBB) permeability.  The compounds represent promising therapeutics for treating chronic pain.   

Treatment Of Lysosomal Storage Disorders

UCLA researchers in the Departments of Neurology have developed a novel treatment for Lysosomal-storage diseases (LSDs) with neurological impairment.

MicroRNA Biomarkers and Therapeutic Targets for Colon Cancer and IBD

Researchers at the UCLA Geffen School of Medicine have identified a novel set of biomarkers consisting of a microRNA and aftiphilin (AFTPH) as an effective means to distinguish between tissues with colon cancer and normal tissues. Other biomarkers within the set are linked specifically with inflammatory bowel disease.

Identification Of OLMAINC as a Biomarker for NAFLD, NASH, Metabolic Syndrome, Hepatic Fibrosis

UCLA researchers in the Departments of Medicine and Human Genetics have identified a sequence of long, non-coding RNA that plays a role in the regulation of intracellular lipogenesis and holds potential for diagnosing and treating metabolic diseases, including NAFLD and NASH.

Chemoselective Side-Chain Modifications Of Methionine-Containing Elastin-Like Polypeptides

UCLA researchers in the Department of Bioengineering and Department of Chemistry & Biochemistry have developed a novel method for the introduction of various functional groups onto recombinant elastin-like polypeptides (ELPs), creating new compositions of ELPs that may be used for medical therapeutic or diagnostic applications.

TGF-Beta Binding Peptides and Tumors

UCLA researchers have developed a method to use TGF-beta binding peptides such as BBP to bind TGF-beta and remove it from solution for treatment of metastatic diseases.

  • Go to Page: